A Phase I Pharmacokinetic Study of MABp1 in Healthy Volunteers
Latest Information Update: 17 Sep 2021
Price :
$35 *
At a glance
- Drugs Bermekimab (Primary)
- Indications Acne vulgaris; Atopic dermatitis; Colorectal cancer; Hidradenitis suppurativa; Non-small cell lung cancer; Pancreatic cancer; Plaque psoriasis; Pyoderma; Systemic scleroderma; Type 2 diabetes mellitus; Vascular restenosis
- Focus Pharmacokinetics; Registrational
- Sponsors Janssen Research & Development; XBiotech
- 26 Jun 2017 Status changed from active, no longer recruiting to completed.
- 22 Feb 2017 According to a XBiotech media release, dosing of subjects has been completed in this trial.
- 22 Feb 2017 Status changed from recruiting to active, no longer recruiting based on announcement of dosing completion in an XBiotech media release.